Zobrazeno 1 - 10
of 123
pro vyhledávání: '"K. Martin Kortüm"'
Autor:
Larissa Haertle, Umair Munawar, Hipólito N. C. Hernández, Andres Arroyo‐Barea, Tobias Heckel, Isabel Cuenca, Lucia Martin, Carlotta Höschle, Nicole Müller, Cornelia Vogt, Thorsten Bischler, Paula L. delCampo, Seungbin Han, Natalia Buenache, Xiang Zhou, Florian Bassermann, Johannes Waldschmidt, Torsten Steinbrunn, Leo Rasche, Thorsten Stühmer, Joaquin Martinez‐Lopez, K. Martin Kortüm, Santiago Barrio
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Abstract Multiple myeloma (MM) is a genetically heterogeneous disease and the management of relapses is one of the biggest clinical challenges. TP53 alterations are established high‐risk markers and are included in the current disease staging crite
Externí odkaz:
https://doaj.org/article/315cbd46c5644a63a5886179cfc26c50
Autor:
Umair Munawar, Xiang Zhou, Sabrina Prommersberger, Silvia Nerreter, Cornelia Vogt, Maximilian J. Steinhardt, Marietta Truger, Julia Mersi, Eva Teufel, Seungbin Han, Larissa Haertle, Nicole Banholzer, Patrick Eiring, Sophia Danhof, Miguel Angel Navarro-Aguadero, Adrian Fernandez-Martin, Alejandra Ortiz-Ruiz, Santiago Barrio, Miguel Gallardo, Antonio Valeri, Eva Castellano, Peter Raab, Maximilian Rudert, Claudia Haferlach, Markus Sauer, Michael Hudecek, J. Martinez-Lopez, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-9 (2023)
Abstract The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms
Externí odkaz:
https://doaj.org/article/91aba52b6c244a118ef7a4278eff963f
Autor:
Umair Munawar, Johanna Theuersbacher, Maximilian J. Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S. Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K. Martin Kortüm, Johannes M. Waldschmidt
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific a
Externí odkaz:
https://doaj.org/article/5b70ffdb59ff4ed5b400827482becc1e
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Multiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of ‘cure’ remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (an
Externí odkaz:
https://doaj.org/article/53e0213da26b41458f1bf7d0c6eec021
Autor:
Xiang Zhou, Seungbin Han, Nadine Cebulla, Larissa Haertle, Maximilian J. Steinhardt, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Emilia Stanojkovska, Julia Mersi, Umair Munawar, Magnus Schindehütte, Robert Blum, Ann-Kristin Reinhold, Oliver Scherf-Clavel, Heike L. Rittner, Mirko Pham, Leo Rasche, Hermann Einsele, Claudia Sommer, K. Martin Kortüm
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-4 (2023)
Abstract We analyzed single nucleotide polymorphisms (SNPs) in PKNOX1 (rs2839629) and in the intergenic region between PKNOX1 and CBS (rs915854) by Sanger sequencing in 88 patients with multiple myeloma treated with bortezomib. All patients (n = 13)
Externí odkaz:
https://doaj.org/article/e043da7190114504a5058138355ee591
Autor:
Maximilian J. Steinhardt, Marietta Truger, Max Bittrich, Xiang Zhou, Julia Noderer, Christine Riedhammer, Xianghui Xiao, Sophia Gawlas, Philipp Weis, Florian Eisele, Claudia Haferlach, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/4de0972e17f046038dc9063235362e22
Autor:
Maximilian J. Steinhardt, Vladimir Cejka, Mengmeng Chen, Sabrina Bäuerlein, Julia Schäfer, Ali Adrah, Sandra M. Ihne-Schubert, Aikaterini Papagianni, K. Martin Kortüm, Caroline Morbach, Stefan Störk
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 1, p 283 (2024)
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibril
Externí odkaz:
https://doaj.org/article/1935ad6cdff84f768034f66589966fc7
Autor:
Xiang Zhou, Andrej Besse, Jessica Peter, Maximilian Johannes Steinhardt, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Emilia Stanojkovska, Xianghui Xiao, Hannah Hornburger, Larissa Haertle, Max Mendez Lopez, Umair Munawar, Angela Riedel, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Bogdan Florea, Hermann Einsele, K. Martin Kortüm, Christoph Driessen, Lenka Besse, Leo Rasche
Publikováno v:
Haematologica, Vol 108, Iss 6 (2023)
Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus high-dose (≥36 mg/m2) carfilzomib in 103 pairs of peripheral blood mononuc
Externí odkaz:
https://doaj.org/article/145781d6796c4523aa127a2cf8216c97
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM. Currently, B-cell matu
Externí odkaz:
https://doaj.org/article/dc78d228034d43dcb980f98f261234ab
Autor:
Estefanía García-Guerrero, Luis G. Rodríguez-Lobato, Belén Sierro-Martínez, Sophia Danhof, Stephan Bates, Silke Frenz, Larissa Haertle, Ralph Götz, Markus Sauer, Leo Rasche, K. Martin Kortüm, Jose A. Pérez-Simón, Hermann Einsele, Michael Hudecek, Sabrina R. Prommersberger
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under thera
Externí odkaz:
https://doaj.org/article/c5afb352d346406386ae305b8e18e44f